Engineering iPSC-derived Natural Killer Cells for Enhanced Efficacy of Cancer Therapies
Originally Aired: March 21st, 2018
In this webinar, Professor Bruce Walcheck discusses current approaches to augment ADCC by NK cells as therapies to treat cancer. This webinar also includes exciting research from his lab focused on generating enhanced versions of CD16A, an Fc receptor expressed by NK cells that recognizes tumor-targeting mAbs. Finally, his discussion covers the genetic manipulation of iPSCs to derive NK cells engineered to express modified CD16A, and their potential for improving the efficacy of tumor-targeting therapeutic mAbs.
Human natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that perform anti-tumor activities without the need for prior antigen sensitization, HLA-restricted antigen recognition, or the risk of graft versus host disease when transferred to patients. NK cells also produce high levels of cytokines that engage the adaptive immune response. Due to these effector activities, primary and induced pluripotent stem cell (iPSC)-derived NK cells are emerging as an important anti-cancer cellular immunotherapy for hematologic and solid malignancies. To this end, GMP-compliant methods to ex vivo expand NK cells for adoptive transfer are being actively developed. A key advantage of NK cells is that they can kill multiple types of cancer by their recognition of anti-tumor antibodies, a process referred to as antibody-dependent cell-mediate cytotoxicity (ADCC). Therapeutic monoclonal antibodies (mAbs) have been generated against a variety of malignancies, and several clinically successful mAbs utilize ADCC as a mechanism of action .